



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/863,786	05/23/2001	Ronnie Palmgren	PU-0124

CONFIRMATION NO. 2351
FORMALITIES LETTER



OC00000006338653

Amersham Pharmacia Biotech, Inc.
800 Centennial Avenue
Piscataway, NJ 08855

Date Mailed: 07/25/2001



NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

10/01/2001 HUONG1 00000021 500588 09863786

01 FC:105 130.00 CH

BEST AVAILABLE COPY

Sector 13


**Response To Notice To File Missing Parts Of Application
Filing Date Granted (PTO-1533)(Large Entity)**

Docket No.
PU-0124

In Re Application Of: **R. Palmgren, et al.**

Serial No.	Filing Date	Examiner	Group Art Unit
09/863,786	May 23, 2001	To be assigned	1645

Invention: **Peptide Fragmentation**



TO THE ASSISTANT COMMISSIONER FOR PATENTS:
Box Missing Parts

This is a response to the Notice to File Missing Parts of Application - Filing Date Granted (PTO-1533) mailed on
July 25, 2001
Date

Enclosed herewith for filing are the following:

- A copy of the Notice to File Missing Parts of Application - Filing Date Granted (PTO-1533). **(REQUIRED)**
- An oath or declaration in compliance with 37 CFR 1.63, including residence information and identifying the application by the above Application Number and Filing Date.
- A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date.
- An oath or declaration in compliance with 37 CFR 1.63 listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date.
- A verified English translation of the non-English language application papers as originally filed. It is requested that this translation be used as the copy for examination purposes in the United States Patent and Trademark Office.
- Other (list):

copy of this transmittal letter for charging purposes
request for a corrected filing receipt
marked up copy of the filing receipt having a mailing date of July 25, 2001
return postcard

BEST AVAILABLE COPY

**Response To Notice To File Missing Parts Of Application
Filing Date Granted (PTO-1533)(Large Entity)**

Docket No.
PU-0124

In Re Application Of: **R. Palmgren, et al.**

Serial No.	Filing Date	Examiner	Group Art Unit
09/863,786	May 23, 2001	To be assigned	1645

Invention: Peptide Fragmentation

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Box Missing Parts

Completion of application fees as calculated below:

Utility application filing fee

Design application filing fee

Total number of independent claims =

Total number of claims =

Multiple dependent claims

Surcharge for late payment of filing fee and/or late filing of original declaration or oath \$130.00

Petition and fee for filing by other than all the inventors or a person not the inventor _____

Fee for processing an application filed with a non-English language specification _____

Fee for processing and retention of application _____

Total completion of application fees **\$130.00**

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the above-identified Notice to File Missing Parts of Application. The requested extension is as follows (check time period desired). If an additional time extension is required, please consider this a petition therefor.

One month Two months Three months Four months Five months

from:

until

Date _____

Data

Total time extension fees \$0.00

Total fees due \$130.00

BEST AVAILABLE COPY

**Response To Notice To File Missing Parts Of Application
Filing Date Granted (PTO-1533) (Large Entity)**

Docket No.

PU-0124

In Re Application Of: **R. Palmgren, et al.**

Serial No.
09/863,786

Filing Date
May 23, 2001

Examiner
To be assigned

Group Art Unit
1645


Invention: **Peptide Fragmentation**

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Box Missing Parts

The fee of **\$130.00** is to be paid as follows:

- A check in the amount of the fee is enclosed.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 500-588
A duplicate copy of this sheet is enclosed.
- If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 500-588
A duplicate copy of this sheet is enclosed.



Signature

**Robert F. Chisholm
Amersham Pharmacia Biotech, Inc.
800 Centennial Avenue
Piscataway, New Jersey 08855**

(732) 980-2930
Reg. No.: 39,939

CC:

Dated: **September 24, 2001**

I certify that this document and fee is being deposited on September 24, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.




Signature of Person Mailing Correspondence

Melissa Leck

Typed or Printed Name of Person Mailing Correspondence

BEST AVAILABLE COPY



receipt
#6

PU-0124

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the: Assistant Commissioner for Patents Washington, D.C. 20231.

Melissa Leak
Type or print name


Signature

September 24, 2001
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: R. Palmgren, et al.
Serial No.: 09/863,786
Filing Date: May 23, 2001
Title: Peptide Fragmentation

Group Art Unit: 1645

Examiner: To be assigned

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Please furnish the undersigned with a corrected filing receipt for the above-identified application. The correction required is as follows:

In the "Applicant(s)" section, please delete the Applicant Eva Wiksell.

Applicants authorize the Commissioner to charge any additional fees that may be necessary, or credit any excess fees paid, to Applicant's Deposit Account Number 500-588.


Enclosed is a marked up copy of the Filing Receipt having a mailing date of July 25, 2001. Any questions can be referred to the undersigned.

Amersham Pharmacia Biotech, Inc.
P.O. Box 1327
800 Centennial Avenue
Piscataway, New Jersey 08855-1327
(732)980-2930 (voice)
(732)457-8463 (facsimile)

Respectfully submitted,



Robert F. Chisholm
Reg. No. 39,939


UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/863,786	05/23/2001	1645	710	PU-0124	19	20	3

CONFIRMATION NO. 2351

FILING RECEIPT



OC000000006338652


Amersham Pharmacia Biotech, Inc.
 800 Centennial Avenue
 Piscataway, NJ 08855

Date Mailed: 07/25/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ronnie Palmgren, Stockholm, SWEDEN;
 Jean-Luc Maloisel, Enebyberg, SWEDEN;
~~Eva Wiksell, Uppsala, SWEDEN~~;
 Maria Liminga, Uppsala, SWEDEN;
 Thomas Woods Keough, Cincinnati, OH;
 Robert Scott Youngquist, Mason, OH;



Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 07/24/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Peptide fragmentation

Preliminary Class

435

Data entry by : QUINTEROS, KARLA

Team : OIPE

Date: 07/25/2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time; if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231